leisure time -WSS

leisure time

author：explore 2025-09-27 09:46:06 - browse：65693

Adam's take main illustration — Molly Ferguson/STAT

Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： New study raises questions about niacin and heart health

WSS

HHS's proposed rule does nothing to address the climate crisis

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

New CMS data security rules will hurt Medicare, Medicaid research

MD Anderson's Padmanee Sharma responds to research credit suit

Researchers tackle phage therapy hurdles for wider adoption

explore

leisure time

Wikipedia

Virginia high school admissions case could be legal follow

MD Anderson's Padmanee Sharma responds to research credit suit

Duchenne breakthrough therapy leaves behind pioneering families

Black vets could get higher VA benefits if race not used in lung test

Duchenne breakthrough therapy leaves behind pioneering families

Measles policy set amid Florida outbreak alarms vaccine proponents

Bright Health sells Medicare Advantage business to Molina

Obamacare plans could cover weight loss drugs

New air purifier tech could be key to improving indoor air quality

Measles policy set amid Florida outbreak alarms vaccine proponents

focus

Measles policy set amid Florida outbreak alarms vaccine proponents

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Welsh Carson private equity firm escapes from FTC antitrust case

FDA warns medical device makers about rise in fabricated data

Abridge raises $150m as clinical notes automation market heats up

Researchers tackle phage therapy hurdles for wider adoption

hotspot

Wikipedia

focus

hotspot